Amgen
Search results
Biogen is a leading global biotechnology company that pioneers science and drives innovations for complex and devastating diseases. Biogen is advancing a pipeline of potential therapies across neurology, neuropsychiatry, specialized immunology and rare disease and remains acutely focused on its purpose of serving humanity through science while ...
- Responsibility
The CoLab, previously the Biogen Community Lab, is a...
- Alzheimer's Disease
Biogen’s commitment to health equity is rooted in efforts...
- Amyotrophic Lateral Sclerosis
Kate was busy planning her wedding when she was diagnosed...
- Lupus
Biogen’s decades of study at the crossroads of neurology and...
- Multiple Sclerosis
Multiple sclerosis (MS) is a complex, heterogeneous, chronic...
- Spinal Muscular Atrophy
SMA, an inherited disease that can have a devastating effect...
- Pipeline
Breaking New Ground With Science. With a strong focus on...
- Responsibility
Biogen is a leading global biotechnology company that pioneers science and drives innovations for complex and devastating diseases. Biogen is advancing a pipeline of potential therapies across neurology, neuropsychiatry, specialized immunology and rare disease and remains acutely focused on its purpose of serving humanity through science while ...
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide. Biogen operates in Argentina, Brazil, Canada, China, France, Germany, Hungary, India, Italy, Japan ...
Breaking New Ground With Science. With a strong focus on difficult-to-treat diseases, our pipeline is focused on research in therapeutic areas where we believe we have the best opportunity to deliver transformational medicines to patients and protect public health.
Biogen is a global biotechnology company that develops innovative medicines for various diseases, including rare and neurological disorders. Follow its LinkedIn page to see its latest news, updates, events, and collaborations in the field of biotechnology research.
FDA Approves LEQEMBI™ (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer's Disease. January 6, 2023. PDF Version. Accelerated Approval is based on Phase 2 data showing a reduction in amyloid-beta plaques in early AD patients treated with LEQEMBI™.
Biogen is a global company that discovers, develops and delivers innovative therapies for neurological and neurodegenerative diseases. Founded in 1978, Biogen has a leading portfolio of medicines for multiple sclerosis, spinal muscular atrophy and other neuroscience fields.
